Does the media refer more to RCUS or BMRN?

In the previous week, BioMarin Pharmaceutical had 28 more articles in the media than Arcus Biosciences. MarketBeat recorded 34 mentions for BioMarin Pharmaceutical and 6 mentions for Arcus Biosciences. BioMarin Pharmaceutical's average media sentiment score of 0.73 beat Arcus Biosciences' score of 0.71 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioMarin Pharmaceutical 13 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Is RCUS or EXEL more profitable?

Exelixis has a net margin of 35.33% compared to Arcus Biosciences' net margin of -393.16%. Exelixis' return on equity of 42.17% beat Arcus Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Arcus Biosciences -393.16% -89.54% -45.61% Exelixis 35.33% 42.17% 31.76%

Does the media prefer RCUS or EXEL?

In the previous week, Exelixis had 10 more articles in the media than Arcus Biosciences. MarketBeat recorded 16 mentions for Exelixis and 6 mentions for Arcus Biosciences. Exelixis' average media sentiment score of 1.18 beat Arcus Biosciences' score of 0.71 indicating that Exelixis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 11 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ARWR or RCUS?

In the previous week, Arrowhead Pharmaceuticals had 9 more articles in the media than Arcus Biosciences. MarketBeat recorded 15 mentions for Arrowhead Pharmaceuticals and 6 mentions for Arcus Biosciences. Arrowhead Pharmaceuticals' average media sentiment score of 0.90 beat Arcus Biosciences' score of 0.71 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcus Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RCUS or MDGL?

In the previous week, Madrigal Pharmaceuticals had 1 more articles in the media than Arcus Biosciences. MarketBeat recorded 7 mentions for Madrigal Pharmaceuticals and 6 mentions for Arcus Biosciences. Madrigal Pharmaceuticals' average media sentiment score of 1.08 beat Arcus Biosciences' score of 0.71 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Madrigal Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RCUS or HALO?

In the previous week, Halozyme Therapeutics had 9 more articles in the media than Arcus Biosciences. MarketBeat recorded 15 mentions for Halozyme Therapeutics and 6 mentions for Arcus Biosciences. Halozyme Therapeutics' average media sentiment score of 1.04 beat Arcus Biosciences' score of 0.71 indicating that Halozyme Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Halozyme Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Arcus Biosciences (RCUS) Competitors

$30.14 +0.62 (+2.10%)

As of 08/21/2026 03:58 PM Eastern

Compare

RCUS vs. BMRN, EXEL, ARWR, MDGL, and HALO

Should you buy Arcus Biosciences stock or one of its competitors? Arcus Biosciences's main competitors and comparable companies include BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Arrowhead Pharmaceuticals (ARWR), Madrigal Pharmaceuticals (MDGL), and Halozyme Therapeutics (HALO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Arcus Biosciences compare to BioMarin Pharmaceutical?

Arcus Biosciences (NYSE:RCUS) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

In the previous week, BioMarin Pharmaceutical had 28 more articles in the media than Arcus Biosciences. MarketBeat recorded 34 mentions for BioMarin Pharmaceutical and 6 mentions for Arcus Biosciences. BioMarin Pharmaceutical's average media sentiment score of 0.73 beat Arcus Biosciences' score of 0.71 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioMarin Pharmaceutical	13 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 7.6% of Arcus Biosciences shares are held by company insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Arcus Biosciences has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

Arcus Biosciences currently has a consensus price target of $37.80, indicating a potential upside of 25.41%. BioMarin Pharmaceutical has a consensus price target of $88.83, indicating a potential upside of 33.17%. Given BioMarin Pharmaceutical's stronger consensus rating and higher possible upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.75

BioMarin Pharmaceutical has higher revenue and earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	15.54	-$353M	-$3.90	N/A
BioMarin Pharmaceutical	$3.22B	4.01	$348.90M	$0.37	180.27

BioMarin Pharmaceutical has a net margin of 2.14% compared to Arcus Biosciences' net margin of -393.16%. BioMarin Pharmaceutical's return on equity of 5.32% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-393.16%	-89.54%	-45.61%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

Summary

BioMarin Pharmaceutical beats Arcus Biosciences on 14 of the 17 factors compared between the two stocks.

How does Arcus Biosciences compare to Exelixis?

Arcus Biosciences (NYSE:RCUS) and Exelixis (NASDAQ:EXEL) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Arcus Biosciences currently has a consensus target price of $37.80, suggesting a potential upside of 25.41%. Exelixis has a consensus target price of $50.07, suggesting a potential downside of 7.42%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Arcus Biosciences is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Exelixis	2 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.30

92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 7.6% of Arcus Biosciences shares are owned by company insiders. Comparatively, 2.6% of Exelixis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Exelixis has a net margin of 35.33% compared to Arcus Biosciences' net margin of -393.16%. Exelixis' return on equity of 42.17% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-393.16%	-89.54%	-45.61%
Exelixis	35.33%	42.17%	31.76%

In the previous week, Exelixis had 10 more articles in the media than Arcus Biosciences. MarketBeat recorded 16 mentions for Exelixis and 6 mentions for Arcus Biosciences. Exelixis' average media sentiment score of 1.18 beat Arcus Biosciences' score of 0.71 indicating that Exelixis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	11 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis has higher revenue and earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	15.54	-$353M	-$3.90	N/A
Exelixis	$2.32B	5.78	$782.57M	$3.18	17.01

Arcus Biosciences has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market.

Summary

Exelixis beats Arcus Biosciences on 10 of the 17 factors compared between the two stocks.

How does Arcus Biosciences compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Arcus Biosciences (NYSE:RCUS) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

In the previous week, Arrowhead Pharmaceuticals had 9 more articles in the media than Arcus Biosciences. MarketBeat recorded 15 mentions for Arrowhead Pharmaceuticals and 6 mentions for Arcus Biosciences. Arrowhead Pharmaceuticals' average media sentiment score of 0.90 beat Arcus Biosciences' score of 0.71 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcus Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arrowhead Pharmaceuticals has a net margin of -47.79% compared to Arcus Biosciences' net margin of -393.16%. Arrowhead Pharmaceuticals' return on equity of -60.06% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%
Arcus Biosciences	-393.16%	-89.54%	-45.61%

Arrowhead Pharmaceuticals presently has a consensus price target of $97.33, indicating a potential upside of 11.74%. Arcus Biosciences has a consensus price target of $37.80, indicating a potential upside of 25.41%. Given Arcus Biosciences' higher possible upside, analysts clearly believe Arcus Biosciences is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 7.6% of Arcus Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Arrowhead Pharmaceuticals has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market.

Arrowhead Pharmaceuticals has higher revenue and earnings than Arcus Biosciences. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	14.79	-$1.63M	-$2.25	N/A
Arcus Biosciences	$247M	15.54	-$353M	-$3.90	N/A

Summary

Arrowhead Pharmaceuticals beats Arcus Biosciences on 11 of the 16 factors compared between the two stocks.

How does Arcus Biosciences compare to Madrigal Pharmaceuticals?

Arcus Biosciences (NYSE:RCUS) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Arcus Biosciences presently has a consensus target price of $37.80, indicating a potential upside of 25.41%. Madrigal Pharmaceuticals has a consensus target price of $689.93, indicating a potential upside of 33.52%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Madrigal Pharmaceuticals is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

Madrigal Pharmaceuticals has higher revenue and earnings than Arcus Biosciences. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	15.54	-$353M	-$3.90	N/A
Madrigal Pharmaceuticals	$958.40M	12.45	-$288.28M	-$12.89	N/A

In the previous week, Madrigal Pharmaceuticals had 1 more articles in the media than Arcus Biosciences. MarketBeat recorded 7 mentions for Madrigal Pharmaceuticals and 6 mentions for Arcus Biosciences. Madrigal Pharmaceuticals' average media sentiment score of 1.08 beat Arcus Biosciences' score of 0.71 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Madrigal Pharmaceuticals has a net margin of -25.32% compared to Arcus Biosciences' net margin of -393.16%. Madrigal Pharmaceuticals' return on equity of -56.65% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-393.16%	-89.54%	-45.61%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

Arcus Biosciences has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -1.01, meaning that its stock price is 201% less volatile than the broader market.

92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 7.6% of Arcus Biosciences shares are owned by company insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Madrigal Pharmaceuticals beats Arcus Biosciences on 12 of the 16 factors compared between the two stocks.

How does Arcus Biosciences compare to Halozyme Therapeutics?

Arcus Biosciences (NYSE:RCUS) and Halozyme Therapeutics (NASDAQ:HALO) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

In the previous week, Halozyme Therapeutics had 9 more articles in the media than Arcus Biosciences. MarketBeat recorded 15 mentions for Halozyme Therapeutics and 6 mentions for Arcus Biosciences. Halozyme Therapeutics' average media sentiment score of 1.04 beat Arcus Biosciences' score of 0.71 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Halozyme Therapeutics	10 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 7.6% of Arcus Biosciences shares are owned by company insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Halozyme Therapeutics has a net margin of 24.86% compared to Arcus Biosciences' net margin of -393.16%. Halozyme Therapeutics' return on equity of 260.98% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-393.16%	-89.54%	-45.61%
Halozyme Therapeutics	24.86%	260.98%	23.91%

Arcus Biosciences has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

Arcus Biosciences presently has a consensus price target of $37.80, indicating a potential upside of 25.41%. Halozyme Therapeutics has a consensus price target of $91.20, indicating a potential downside of 15.69%. Given Arcus Biosciences' higher probable upside, analysts clearly believe Arcus Biosciences is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

Halozyme Therapeutics has higher revenue and earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	15.54	-$353M	-$3.90	N/A
Halozyme Therapeutics	$1.66B	7.38	$316.89M	$3.35	32.29

Summary

Halozyme Therapeutics beats Arcus Biosciences on 13 of the 16 factors compared between the two stocks.

Get Arcus Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RCUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RCUS vs. The Competition

Export

Metric	Arcus Biosciences	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$3.86B	$4.01B	$7.37B	$24.30B
Dividend Yield	N/A	3.64%	2.53%	3.70%
P/E Ratio	-7.73	11.62	272.88	30.31
Price / Sales	15.54	1,338.17	618.96	19.89
Price / Cash	N/A	105.14	78.62	32.49
Price / Book	8.28	16.80	13.05	6.77
Net Income	-$353M	-$12.50M	$3.47B	$1.07B
7 Day Performance	2.18%	3.29%	2.09%	-0.65%
1 Month Performance	1.44%	8.23%	6.64%	3.38%
1 Year Performance	186.80%	55.05%	25.02%	14.90%

Arcus Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RCUS Arcus Biosciences	2.998 of 5 stars	$30.14 +2.1%	$37.80 +25.4%	+186.8%	$3.86B	$247M	N/A	500
BMRN BioMarin Pharmaceutical	4.7589 of 5 stars	$66.64 -1.1%	$88.45 +32.7%	+13.9%	$13.04B	$3.41B	180.11	3,221	Analyst Forecast
EXEL Exelixis	3.3988 of 5 stars	$52.32 +2.1%	$49.79 -4.8%	+40.0%	$12.96B	$2.44B	16.45	1,077	News Coverage Positive News Analyst Forecast
ARWR Arrowhead Pharmaceuticals	2.2776 of 5 stars	$88.70 +2.4%	$97.33 +9.7%	+308.4%	$12.20B	$829.45M	N/A	400	News Coverage Insider Trade
MDGL Madrigal Pharmaceuticals	3.8071 of 5 stars	$524.87 +3.4%	$689.93 +31.4%	+24.6%	$11.73B	$958.40M	N/A	90	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:RCUS) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arcus Biosciences (RCUS) Competitors

RCUS vs. BMRN, EXEL, ARWR, MDGL, and HALO

How does Arcus Biosciences compare to BioMarin Pharmaceutical?

Summary

How does Arcus Biosciences compare to Exelixis?

Summary

How does Arcus Biosciences compare to Arrowhead Pharmaceuticals?

Summary

How does Arcus Biosciences compare to Madrigal Pharmaceuticals?

Summary

How does Arcus Biosciences compare to Halozyme Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCUS vs. The Competition

Arcus Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arcus Biosciences (RCUS) Competitors

RCUS vs. BMRN, EXEL, ARWR, MDGL, and HALO

How does Arcus Biosciences compare to BioMarin Pharmaceutical?

Does the media refer more to RCUS or BMRN?

Do institutionals and insiders believe in RCUS or BMRN?

Which has more risk & volatility, RCUS or BMRN?

Do analysts rate RCUS or BMRN?

Which has better valuation & earnings, RCUS or BMRN?

Is RCUS or BMRN more profitable?

Summary

How does Arcus Biosciences compare to Exelixis?

Do analysts recommend RCUS or EXEL?

Do insiders & institutionals hold more shares of RCUS or EXEL?

Is RCUS or EXEL more profitable?

Does the media prefer RCUS or EXEL?

Which has higher earnings & valuation, RCUS or EXEL?

Which has more risk and volatility, RCUS or EXEL?

Summary

How does Arcus Biosciences compare to Arrowhead Pharmaceuticals?

Does the media prefer ARWR or RCUS?

Is ARWR or RCUS more profitable?

Do analysts recommend ARWR or RCUS?

Do institutionals & insiders have more ownership in ARWR or RCUS?

Which has more risk & volatility, ARWR or RCUS?

Which has stronger earnings & valuation, ARWR or RCUS?

Summary

How does Arcus Biosciences compare to Madrigal Pharmaceuticals?

Do analysts recommend RCUS or MDGL?

Which has preferable earnings & valuation, RCUS or MDGL?

Does the media refer more to RCUS or MDGL?

Is RCUS or MDGL more profitable?

Which has more risk and volatility, RCUS or MDGL?

Do institutionals and insiders believe in RCUS or MDGL?

Summary

How does Arcus Biosciences compare to Halozyme Therapeutics?

Does the media refer more to RCUS or HALO?

Do insiders and institutionals have more ownership in RCUS or HALO?

Is RCUS or HALO more profitable?

Which has more risk and volatility, RCUS or HALO?

Do analysts prefer RCUS or HALO?

Which has stronger earnings & valuation, RCUS or HALO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCUS vs. The Competition

Arcus Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools